These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28832788)

  • 1. [How much does the backlog on drug patents cost for health in Brazil?].
    Jannuzzi AHL; Vasconcellos AG
    Cad Saude Publica; 2017 Aug; 33(8):e00206516. PubMed ID: 28832788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Brazil's pharma patent landscape.
    Gosain R
    Pharm Pat Anal; 2016 Sep; 5(6):385-390. PubMed ID: 27804784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The consequences of 'double examination' for pharmaceutical patent applications in Brazil.
    Salerno G
    Pharm Pat Anal; 2017 Mar; 6(2):49-51. PubMed ID: 28274178
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceutical patent term extension and patent prosecution in Brazil (1997-2018).
    Mercadante E; Paranhos J
    Cad Saude Publica; 2022; 38(1):e00043021. PubMed ID: 35107507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?
    Mueller LL; Taketsuma Costa SM
    Expert Opin Ther Pat; 2014 Jan; 24(1):1-4. PubMed ID: 24206261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Making tenofovir accessible in the brazilian public health system: patent conflicts and generic production.
    Veras J
    Dev World Bioeth; 2014 Aug; 14(2):92-100. PubMed ID: 24889312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Government Patent Use': A Legal Approach To Reducing Drug Spending.
    Kapczynski A; Kesselheim AS
    Health Aff (Millwood); 2016 May; 35(5):791-7. PubMed ID: 27140984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. US files WTO complaints against Brazil over requirement for "local working" of patents.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2000; 5(4):28. PubMed ID: 11833162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Usefulness of Compulsory Licensing in Developing Countries: A Comparative Study of Thai and Brazilian Experiences Regarding Access to Aids Treatments.
    Guennif S
    Dev World Bioeth; 2017 Aug; 17(2):90-99. PubMed ID: 27699996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taking TRIPS to India--Novartis, patent law, and access to medicines.
    Mueller JM
    N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
    [No Abstract]   [Full Text] [Related]  

  • 12. Expanding Access and Reducing Prices for Drugs to Prevent HIV: Should Government Enforce Its Patent Rights Against the Pharmaceutical Industry?
    Gostin LO; Rai AK
    JAMA; 2020 Mar; 323(9):821-822. PubMed ID: 32125411
    [No Abstract]   [Full Text] [Related]  

  • 13. Preliminary injunctions in generic and branded patent litigation.
    Cohen S; England P
    Expert Opin Ther Pat; 2013 Sep; 23(9):1083-6. PubMed ID: 23855903
    [No Abstract]   [Full Text] [Related]  

  • 14. Why are generic drugs being held up in transit? Intellectual property rights, international trade, and the right to health in Brazil and beyond.
    Rosina MS; Shaver L
    J Law Med Ethics; 2012; 40(2):197-205. PubMed ID: 22789040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India.
    Jain D; Darrow JJ
    Health Matrix Clevel; 2013; 23(2):425-57. PubMed ID: 24341078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The new patent regime and disease priorities in India.
    Gupta I; Guin P; Trivedi M
    Glob Public Health; 2013; 8(1):37-54. PubMed ID: 22845021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patent watch.
    Harrison C
    Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274462
    [No Abstract]   [Full Text] [Related]  

  • 18. Patent first, ask questions later: morality and biotechnology in patent law.
    Bagley MA
    William Mary Law Rev; 2003 Dec; 45(2):469-547. PubMed ID: 15570677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is India ready to lead the battle for fair access to medicines?
    Lancet Oncology
    Lancet Oncol; 2013 May; 14(6):437. PubMed ID: 23639313
    [No Abstract]   [Full Text] [Related]  

  • 20. Expedited pharma patenting in Brazil.
    Moreira P
    Pharm Pat Anal; 2019 Mar; 8(2):51-59. PubMed ID: 30887881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.